Abstract
After an initial test and introductory phase characterized by openness and optimism, many new diagnostic and therapeutic methods ultimately result in varying degrees of disappointment. The improvement and quality control of the clinical studies that are needed for the tests by the Institute for Quality and Efficiency in Health Care and the Federal Joint Committee and for the transition of innovations into reimbursable services in light of limited financial resources have not be able to slow, let alone stop, this trend. The fact that even studies designed and conducted according to strict criteria can yield positive results even though there is actually no positive effect or there are even disadvantages is often because the occurrence of systematic errors, referred to as a bias, is given insufficient consideration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
